company background image
ENZY logo

Enzymatica OM:ENZY Stock Report

Last Price

kr3.25

Market Cap

kr533.8m

7D

1.6%

1Y

16.1%

Updated

28 Mar, 2024

Data

Company Financials +

Enzymatica AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enzymatica
Historical stock prices
Current Share Pricekr3.25
52 Week Highkr4.43
52 Week Lowkr2.10
Beta-0.072
1 Month Change6.38%
3 Month Change-17.62%
1 Year Change16.07%
3 Year Change-69.51%
5 Year Change44.44%
Change since IPO-56.08%

Recent News & Updates

Recent updates

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 22
Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Feb 18
Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Jan 12
Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Jul 20
Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Revenue Downgrade: Here's What Analysts Forecast For Enzymatica AB (STO:ENZY)

May 02
Revenue Downgrade: Here's What Analysts Forecast For Enzymatica AB (STO:ENZY)

Enzymatica AB (STO:ENZY) Analysts Just Cut Their EPS Forecasts

Mar 25
Enzymatica AB (STO:ENZY) Analysts Just Cut Their EPS Forecasts

Insider Buying: The Enzymatica AB (STO:ENZY) Director Just Bought kr102k Worth Of Shares

Mar 16
Insider Buying: The Enzymatica AB (STO:ENZY) Director Just Bought kr102k Worth Of Shares

Enzymatica AB (STO:ENZY) Is About To Turn The Corner

Mar 07
Enzymatica AB (STO:ENZY) Is About To Turn The Corner

Is Enzymatica AB's (STO:ENZY) Shareholder Ownership Skewed Towards Insiders?

Jan 23
Is Enzymatica AB's (STO:ENZY) Shareholder Ownership Skewed Towards Insiders?

A Look At The Intrinsic Value Of Enzymatica AB (STO:ENZY)

Jan 02
A Look At The Intrinsic Value Of Enzymatica AB (STO:ENZY)

Trade Alert: The Independent Director Of Enzymatica AB (STO:ENZY), Louise Nicolin, Has Just Spent kr483k Buying 104% More Shares

Dec 15
Trade Alert: The Independent Director Of Enzymatica AB (STO:ENZY), Louise Nicolin, Has Just Spent kr483k Buying 104% More Shares

Shareholder Returns

ENZYSE PharmaceuticalsSE Market
7D1.6%3.0%1.9%
1Y16.1%81.6%17.1%

Return vs Industry: ENZY underperformed the Swedish Pharmaceuticals industry which returned 81.6% over the past year.

Return vs Market: ENZY matched the Swedish Market which returned 17.1% over the past year.

Price Volatility

Is ENZY's price volatile compared to industry and market?
ENZY volatility
ENZY Average Weekly Movement7.8%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement6.1%
10% most volatile stocks in SE Market12.9%
10% least volatile stocks in SE Market3.4%

Stable Share Price: ENZY has not had significant price volatility in the past 3 months.

Volatility Over Time: ENZY's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200718Claus Egstrandhttps://www.enzymatica.se

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that prevents common cold and reduces the duration of illness. It also provides enzyme formulations.

Enzymatica AB (publ) Fundamentals Summary

How do Enzymatica's earnings and revenue compare to its market cap?
ENZY fundamental statistics
Market capkr533.83m
Earnings (TTM)-kr49.73m
Revenue (TTM)kr50.90m

10.5x

P/S Ratio

-10.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENZY income statement (TTM)
Revenuekr50.90m
Cost of Revenuekr19.04m
Gross Profitkr31.86m
Other Expenseskr81.59m
Earnings-kr49.73m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 09, 2024

Earnings per share (EPS)-0.30
Gross Margin62.59%
Net Profit Margin-97.69%
Debt/Equity Ratio34.1%

How did ENZY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.